North Shore Hematology/Oncology Associates

East Setauket, New York 11733-3456

1 studies enrolling now · 23 studies all time

What they study most

Advanced Breast Cancer, Advanced Lymphoma, Advanced Prostate Cancer, Advanced Solid Tumor, Breast Cancer, CRPC, Cancer of the Breast, Carcinoma, Non-Small-Cell Lung, Castration-resistant Prostate Cancer, Chronic Myelomonocytic Leukemia (CMML), Colorectal Cancer, DLBCL Transformed From Indolent Lymphoma

Studies at this site

• A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas — Recruiting now
• Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer — Stopped early
• ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer — Completed
• A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer — Completed
• Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442) — Completed
• A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer — Completed
• Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer — Completed
• SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) — Completed
• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant — Completed
• Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) — Stopped early
• Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer — Completed
• Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer — Completed
• E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer — Completed
• Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive — NO_LONGER_AVAILABLE
• A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer — Completed
• CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) — Completed
• A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer — Completed
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas — Stopped early
• MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients — Stopped early
• Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL — Stopped early
• A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC — Stopped early
• Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer — Completed
• Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy — Completed